Migalastat improves diarrhea in patients with Fabry disease:clinical-biomarker correlations from the phase 3 FACETS trial by Schiffmann, Raphael et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Migalastat improves diarrhea in patients with Fabry disease
Schiffmann, Raphael; Bichet, Daniel G; Jovanovic, Ana; Hughes, Derralynn A; Giugliani,
Roberto; Feldt-Rasmussen, Ulla; Shankar, Suma P; Barisoni, Laura; Colvin, Robert B;
Jennette, J Charles; Holdbrook, Fred; Mulberg, Andrew; Castelli, Jeffrey P; Skuban, Nina;
Barth, Jay A; Nicholls, Kathleen
Published in:
Orphanet Journal of Rare Diseases
DOI:
10.1186/s13023-018-0813-7
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Schiffmann, R., Bichet, D. G., Jovanovic, A., Hughes, D. A., Giugliani, R., Feldt-Rasmussen, U., ... Nicholls, K.
(2018). Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the
phase 3 FACETS trial. Orphanet Journal of Rare Diseases, 13, [68]. https://doi.org/10.1186/s13023-018-0813-7
Download date: 03. Feb. 2020
RESEARCH Open Access
Migalastat improves diarrhea in patients
with Fabry disease: clinical-biomarker
correlations from the phase 3 FACETS trial
Raphael Schiffmann1,14*, Daniel G. Bichet2, Ana Jovanovic3, Derralynn A. Hughes4, Roberto Giugliani5,
Ulla Feldt-Rasmussen6, Suma P. Shankar7,13, Laura Barisoni8, Robert B. Colvin9, J. Charles Jennette10,
Fred Holdbrook11, Andrew Mulberg11, Jeffrey P. Castelli11, Nina Skuban11, Jay A. Barth11 and Kathleen Nicholls12
Abstract
Background: Fabry disease is frequently characterized by gastrointestinal symptoms, including diarrhea. Migalastat
is an orally-administered small molecule approved to treat the symptoms of Fabry disease in patients with
amenable mutations.
Methods: We evaluated minimal clinically important differences (MCID) in diarrhea based on the corresponding
domain of the patient-reported Gastrointestinal Symptom Rating Scale (GSRS) in patients with Fabry disease and
amenable mutations (N = 50) treated with migalastat 150 mg every other day or placebo during the phase 3
FACETS trial (NCT00925301).
Results: After 6 months, significantly more patients receiving migalastat versus placebo experienced improvement
in diarrhea based on a MCID of 0.33 (43% vs 11%; p = .02), including the subset with baseline diarrhea (71% vs 20%;
p = .02). A decline in kidney peritubular capillary globotriaosylceramide inclusions correlated with diarrhea
improvement; patients with a reduction > 0.1 were 5.6 times more likely to have an improvement in diarrhea than
those without (p = .031).
Conclusions: Migalastat was associated with a clinically meaningful improvement in diarrhea in patients with Fabry
disease and amenable mutations. Reductions in kidney globotriaosylceramide may be a useful surrogate endpoint
to predict clinical benefit with migalastat in patients with Fabry disease.
Trial registration: NCT00925301; June 19, 2009.
Keywords: Amenable mutation, Diarrhea, Fabry disease, Gastrointestinal, Globotriaosylceramide, GSRS, Lyso-Gb3,
Migalastat, Pharmacological chaperone
Background
Fabry disease is a rare, progressive, life-threatening X-
linked lysosomal storage disorder, affecting males and fe-
males, with an estimated prevalence of 1:117,000 to 1:
40,000 [1, 2]. Mutations in the GLA gene can lead to a
deficiency of the lysosomal enzyme α-galactosidase A,
which in turn results in an accumulation of glycosphingo-
lipids, including globotriaosylceramide (GL-3) and plasma
globotriaosylsphingosine (lyso-Gb3), and subsequently the
debilitating signs, symptoms, and life-limiting sequelae of
Fabry disease [3]. Intrafamilial phenotypic variability is
common in Fabry disease [4] and other genetic disorders,
such as muscular dystrophy [5], making it difficult to pro-
vide an accurate prognosis to patients based only on
family history. Levels of disease substrate have been used
as biomarkers in various clinical studies in Fabry disease
[6, 7]; however, the correlation of changes in these bio-
markers with clinical variables remains limited.
Gastrointestinal signs and symptoms are a prominent
and clinically important manifestation of Fabry disease
and are reported by at least half of patients [8, 9]. Com-
mon gastrointestinal signs and symptoms associated
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with Fabry disease include diarrhea, nausea, vomiting,
abdominal pain, and constipation [10, 11]. Gastrointes-
tinal manifestations of Fabry disease are reported from
an early age, and often have profound negative effects
on social and economic functioning and quality of life in
patients [11, 12].
Migalastat is a pharmacological chaperone designed to
bind selectively and reversibly with high affinity to the
active sites of certain mutant forms of α-galactosidase
(amenable GLA mutations) [13, 14]. Chaperoning mutated
α-galactosidase A to lysosomes may mimic natural en-
zyme trafficking, which has been suggested to result in
more consistent α-galactosidase A activity than current
standard of care enzyme replacement therapy (ERT) [15].
In the phase 3 FACETS trial, which included a 6-
month placebo-controlled stage, treatment with migala-
stat maintained stable renal function, reduced cardiac
mass, and reduced the severity of gastrointestinal signs
and symptoms (diarrhea, reflux, and indigestion do-
mains) in patients with Fabry disease and amenable
mutations [15]. In the phase 3, active-controlled AT-
TRACT study, migalastat and ERT had similar effects on
renal function in patients with Fabry disease and amen-
able mutations, and cardiac mass decreased significantly
with migalastat treatment (compared with no change
with ERT); furthermore, migalastat was generally safe
and well-tolerated [16]. These results led to the approval
of migalastat in the European Union, Switzerland,
Canada, Australia, Republic of Korea, Japan, and Israel
for the treatment of Fabry disease in patients aged
16 years and older with amenable mutations [14, 17].
We report here the results of further analyses using
minimal clinically important difference (MCID) to evalu-
ate improvements in diarrhea using the patient-reported
Gastrointestinal Symptom Rating Scale (GSRS), in
patients with Fabry disease treated with migalastat in the
FACETS study. We also examine whether reductions in
kidney peritubular capillary (PTC) GL-3 or lyso-Gb3 can
be used as a surrogate endpoint to predict clinical bene-
fit with migalastat.
Methods
Study design and patients
The FACETS trial (AT1001–011, NCT00925301) has been
described previously [15]. In brief, the study consisted of a
6-month randomized, double-blind, placebo-controlled
phase, followed by a 6-month open-label phase with
cross-over of placebo-treated patients to migalastat, and a
12-month extension phase. Male and female patients aged
16 to 74 years with Fabry disease, who were naive to ERT
or had not received ERT for at least 6 months before
screening, were eligible for randomization [15]. The effect
of migalastat on gastrointestinal symptoms was evaluated
in patients with GLA mutations amenable to migalastat
(N = 50) [13].
Gastrointestinal symptoms rating scale
The GSRS comprises 15 questions that assess the sever-
ity of 5 domains: diarrhea (“GSRS-D”), abdominal pain,
constipation, indigestion, and reflux. Each domain
consists of 2–4 questions, each rated on a 7-point Likert
scale (from 1—absence of burden to 7—very severe dis-
comfort) [18]. The GSRS-D has 3 questions to assess
diarrhea frequency, consistency, and urgency; scores
were determined by calculating the mean of the items
within this domain. Results were collected at baseline
and months 6, 12, 18, and 24 for all patients with amen-
able mutations, and for the subset of patients presenting
with gastrointestinal signs and symptoms at baseline.
GL-3 levels in kidney peritubular capillaries
Detailed methodology and results of the qualitative assess-
ments of kidney biopsies have been reported [15, 19].
Briefly, kidney biopsies were performed at baseline and at
months 6 and 12; these were assessed by 3 independent
pathologists using whole slide images at 100× magnifica-
tion in at least 300 peritubular capillaries in each biopsy to
quantify the average number of GL-3 inclusions per PTC.
Response to treatment was defined as a reduction of > 0.1
inclusions per capillary (which is above the level of
background staining).
Plasma lyso-Gb3
Plasma lyso-Gb3 levels were assessed at baseline and at
months 6 and 12, and analyzed by means of liquid
chromatography-mass spectroscopy [15]. The liquid
chromatography-mass spectroscopy plasma lyso-Gb3
method used a novel stable isotope-labeled internal
standard, 13C6-lyso-Gb3 (lower-limit-of-quantification: 0.
200 ng/mL, 0.254 nmol/L) [20, 21]. Response to
treatment was defined as any reduction from baseline.
Statistical analyses
The mean change in GSRS scores from baseline to
month 6 was a pre-specified endpoint in the FACETS
study. Change from baseline was presented descriptively;
statistical tests of significance were performed using an
ANCOVA model that included treatment, baseline, and
treatment-by-baseline interaction. The p-value was calcu-
lated based on the comparison of the least squares means.
A response in the GSRS-D was defined as a reduction
of 0.33 from baseline (i.e., MCID). The MCID was based
on estimates in the literature for several non-Fabry
gastrointestinal disorders in which diarrhea is a promin-
ent symptom, and is consistent with an estimate of
MCID based on data in Fabry patients from the FACETS
study. Specifically, the MCID of 0.33 was derived from
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anchor-based methodologies from liver transplant pa-
tients with gastrointestinal symptoms (MCID = 0.33)
[22], patients with autoimmune disease with and without
gastrointestinal symptoms (MCID = 0.33) [23], and renal
transplant patients with and without gastrointestinal
symptoms (MCID = 0.40) [24]. A distribution-based esti-
mate of MCID in Fabry disease was derived from the
change from baseline data in the placebo arm of the
FACETS study. Using this approach, an MCID of 0.35 was
generated, based on half the standard deviation [22, 23],
supporting an MCID for GSRS-D of 0.33 in Fabry pa-
tients. A sensitivity analysis using a higher threshold of 0.
66 was also performed to confirm the results.
The number of patients demonstrating a response in
GSRS-D and/or PTC GL-3 from baseline to month 6
was compared between treatment groups. A retrospect-
ive analysis using Xu’s statistic, a multivariate test used
to assess if treatment has a beneficial effect on multiple
outcomes simultaneously [25], evaluated whether treat-
ment impacted both parameters as a combined endpoint.
Logistic regression was used to assess the correlation be-
tween changes in GSRS-D and PTC GL-3. A similar re-
gression analysis was performed to assess the correlation
between changes in GSRS-D and plasma lyso-Gb3.
Pre-specified analyses were conducted for all patients
with amenable mutations and, post hoc, for the subset
of patients with amenable mutations who reported diar-
rhea symptoms at baseline.
Results
Summary of GSRS findings
Of the 50 patients with Fabry disease and amenable mu-
tations who were enrolled in the FACETS study, 28
(56%) reported diarrhea symptoms at baseline.
As previously reported [15], in patients randomly
assigned to migalastat (n = 28), symptoms of diarrhea,
based on the GSRS-D, improved within the first 6 months
of treatment (change from baseline, − 0.3), whereas diar-
rhea in the placebo-treated group (n = 22) worsened
(change from baseline, + 0.2; p = .03). A numerically larger
reduction in GSRS-D scores was also observed in the sub-
group of patients who reported gastrointestinal symptoms
at baseline (migalastat change from baseline, − 0.6; pla-
cebo change from baseline, + 0.2). These improvements
continued through 24 months of treatment [15].
Minimal clinically important difference analysis
After 6 months of treatment, 12/28 (43%) migalastat-
treated patients experienced a GSRS-D score improve-
ment of 0.33 (i.e., MCID) compared with 2/19 (11%) pa-
tients receiving placebo (p = .02) (Fig. 1a, b). In the
subset of patients with diarrhea symptoms at baseline
(baseline GSRS-D scores ≥1), 12/17 (71%) of the
migalastat-treated patients experienced a clinically relevant
improvement of 0.33 compared with 2/10 (20%) of
placebo-treated patients (p = .02) (Fig. 1a, b).
Sensitivity analyses
The results of the MCID analysis for observed im-
provement in diarrhea were confirmed in a sensitivity
analysis. Using an improvement threshold of 0.66, 9/
28 (32%) migalastat-treated patients experienced a
clinically relevant change compared with 1/19 (5%)
placebo-treated patients (p = .03). In patients with diarrhea
symptoms at baseline (baseline GSRS-D score of ≥1), 9/13
(69%) migalastat-treated patients experienced a clinically
relevant change compared with 1/9 (11%) placebo-treated
patients (p = .01) (Fig. 1c).
GSRS-D and kidney GL-3 inclusions
As previously reported, 6 months of migalastat
treatment was associated with a significantly greater
reduction in the mean number of GL-3 inclusions per
PTC compared with placebo (− 0.25 vs + 0.07;
p = .008) [15]. An analysis conducted on a combined
endpoint of mean change from baseline in PTC GL-3
inclusions and GSRS-D using Xu’s statistic demon-
strated a significant treatment effect of migalastat ver-
sus placebo (1-sided; p = .009).
Assessment of patient-level responses demonstrated a
consistent beneficial effect of migalastat on PTC GL-3
inclusions and GSRS-D. A majority of patients with
amenable mutations (15/18; 83%) treated with migalastat
demonstrated a response in PTC GL-3 and/or GSRS-
D when either or both of these endpoints were ele-
vated at baseline, compared with 5/15 (33%) patients
treated with placebo.
A logistic regression modeling the improvement in
GSRS-D (ie, change from baseline to Month 6 < − 0.
33) as the dependent variable, and reduction in PTC
GL-3 inclusions (ie, change from baseline <− 0.1, ≥ − 0.1)
and treatment group as independent variables, indicated
that reductions in PTC GL-3 inclusions were strongly
associated with improvement in diarrhea (Table 1).
Patients who had a reduction of > 0.1 in PTC GL-3
inclusions (ie, change from baseline <− 0.1) were 5.6
times more likely to have an improvement in
diarrhea symptoms than patients who did not have a
reduction (p = .031).
GSRS-D and plasma lyso-Gb3
When the same correlation analysis was performed
for changes in plasma lyso-Gb3, defined as any reduc-
tion from baseline, and a response in GSRS-D, de-
fined as any reduction ≥0.33, the linear correlation
was not statistically significant (odds ratio = 2.5; 95%
confidence interval 0.63–9.6; p = .2). When the logistic
regression was conducted excluding patients with
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missing data, the odds ratio was similar for PTC GL-
3 (odds ratio = 6.6; 95% confidence interval, 1.3–33.0;
p = .02) and plasma lyso-Gb3 (odds ratio = 6.2; 95%
confidence interval, 0.6–64.3; p = .12); however, statis-
tical significance was achieved only for PTC GL-3,
possibly due to the smaller sample size for plasma
lyso-Gb3 (PTC GL-3, n = 44; plasma lyso-Gb3, n = 31).
Discussion
In this investigation, migalastat was associated with a
clinically relevant improvement in diarrhea symptoms
based on the GSRS-D in patients with Fabry disease
treated during the phase 3 FACETS trial. Based on the
estimated MCID of 0.33, statistically significantly more
patients treated with migalastat achieved a clinically
a
b
c
Fig. 1 Patients experiencing a minimal clinically important difference in GSRS-D scores after 6 months of treatment. a Improvement of 0.33. b Forest
plot showing the effect size of migalastat treatment vs placebo. c Sensitivity analysis: improvement of 0.66
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meaningful improvement in diarrhea symptoms versus
those receiving placebo (43% vs 11%; p = .02) after
6 months of treatment. This statistical significance was
maintained when the analysis was restricted to only pa-
tients with diarrhea symptoms at baseline (71% vs 20%;
p = .02). A sensitivity analysis using a higher MCID
threshold of 0.66 supports these findings. Additionally, a
correlation between reduction of PTC GL-3 inclusions
and diarrhea improvement was observed; patients with a
PTC GL-3 inclusion reduction of > 0.1 were 5.6 times
more likely to also have improvement in diarrhea symp-
toms (p = .031). The correlation between reduction in
the other disease substrate, plasma lyso-Gb3, and im-
provement in GSRS-D was nonsignificant; a small sam-
ple size may have confounded this result.
Diarrhea is among the most common and most
troublesome of the gastrointestinal symptoms experi-
enced by Fabry patients. The abnormal accumulation of
GL-3 in neurons of the peripheral nervous system,
resulting in altered autonomic function and gastrointes-
tinal disturbances, may contribute to the high prevalence
of gastrointestinal symptoms in patients with Fabry dis-
ease [26, 27]. Since up to 67% of patients report that
they experience gastrointestinal symptoms, including
diarrhea, some or all of the time [12], and patients re-
port as many as 12 bouts of diarrhea per day [28], symp-
toms can result in significantly reduced quality of life
[11]. Thus, reduction in the severity and frequency of
diarrhea can be particularly important for patients. Data
from open-label studies with ERT have previously re-
ported improvements in gastrointestinal symptoms fol-
lowing treatment with agalsidase alfa [11] or agalsidase
beta [10]. After 12 months of ERT, agalsidase alfa re-
duced the prevalence of diarrhea by 8% [11]; similarly,
following 6–7 months of therapy with agalsidase beta,
episodes of diarrhea were reduced, and remained rare or
occasional while therapy was maintained (≥3 years) [10].
Our results suggest a similar, clinically relevant improve-
ment in diarrhea symptoms with migalastat treatment.
The analyses presented add to previously published
data demonstrating that migalastat improves gastrointes-
tinal signs and symptoms in patients with Fabry disease.
In the FACETS study, gastrointestinal signs and
symptoms were common, with diarrhea occurring in
56% of patients with amenable mutations at baseline
based on the diarrhea domain of the patient-reported
GSRS [15]. As previously reported, 6 months of treatment
with migalastat resulted in a significant improvement in
diarrhea and reflux compared with placebo-treated pa-
tients; for diarrhea, this improvement was sustained over
24 months [15]. Over this time, there was also a signifi-
cant improvement in indigestion and a trend towards
improvement in constipation [15].
In the FACETS trial, migalastat reduced substrate
levels of GL-3 in patients with Fabry disease [15]. It has
been postulated in the literature that GL-3 deposition in
endothelial intestinal vasculature and enteric ganglia
may contribute to the gastrointestinal manifestations of
Fabry disease, with both cell types shown to accumulate
GL-3 in Fabry patients with gastrointestinal symptoms
[10, 29, 30]. Abnormal function of the enteric plexi is
recognized as a potential mechanism causing irritable
bowel syndrome, for which patients report similar
gastrointestinal symptoms to Fabry disease [28]. Al-
though GL-3 levels in the gastrointestinal tract were not
assessed in this study, we hypothesized that other mea-
sures of disease substrate (i.e., PTC GL-3 and plasma
lyso-Gb3) would likely reflect GL-3 changes in the
gastrointestinal system, and may be correlated with im-
provements in gastrointestinal symptoms. Thus, we ex-
plored the correlation between reduction in kidney GL-3
inclusions and improvement in GSRS-D scores. The re-
sults indicate that reductions in PTC GL-3 inclusions
were significantly associated with improvements in diar-
rhea (GSRS-D scores). Possibly due to the smaller data
set available for lyso-Gb3, no statistically significant asso-
ciation was observed between plasma lyso-Gb3 and
GSRS-D scores. Additional studies exploring the poten-
tial for plasma lyso-Gb3 to be used as a surrogate end-
point are warranted. Based on these results, reductions
in GL-3 could be useful as a surrogate endpoint for
predicting clinical benefit (i.e., improvement in diarrhea)
with migalastat in patients with Fabry disease.
One limitation of these analyses is that the GSRS has
not been validated specifically in Fabry disease. Nonethe-
less, acceptable psychometric properties of the GSRS,
including reliability, stability, and construct validity, have
been established in patients with irritable bowel syn-
drome, gastroesophageal reflux disorder, and dyspepsia
[18, 31–33]. Across these studies, the GSRS-D has
demonstrated consistently strong psychometric proper-
ties with reliability (Cronbach’s α) between 0.72–0.84,
test-retest stability (intra-class correlation coefficient)
between 0.38–0.70, and construct validity, as evidenced
by correlations with various health-related quality of life
instruments including SF-36, Quality of Life in Reflux
and Dyspepsia (QOLRAD), and Psychological General
Table 1 Logistic regression assessing correlation between
PTC GL-3 reductions and GSRS-D improvement (patients with
amenable mutations)
Parameter and Criteria Odds Ratio 95% CI of Odds Ratio
GSRS-D Reduction From
Baseline of 0.33 (n = 50)
5.55 (1.17–26.26)
p = .031
Kidney Peritubular Capillary
GL-3 Reduction From Baseline > 0.1
CI confidence interval, GL-3 globotriaosylceramide, GSRS-D Gastrointestinal
Symptoms Rating Scale—diarrhea
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Well-being (PGWB) [32, 33]. These psychometric prop-
erties make a case for further use, examination, and per-
haps, validation, of the GSRS in the Fabry patient
population. An additional limitation is that the reported
p-values are nominal p-values that have not been
adjusted for multiplicity. As such, these should be inter-
preted with caution.
Conclusions
To our knowledge, the FACETS study is the only double-
blind, placebo-controlled study to evaluate gastrointestinal
signs and symptoms in patients with Fabry disease. Re-
sponder analyses demonstrate that migalastat provided a
clinically meaningful reduction in diarrhea in patients with
Fabry disease and amenable mutations. These data add to
the evidence that migalastat improves gastrointestinal
signs and symptoms, including diarrhea, reflux, and indi-
gestion, in patients with Fabry disease [15]. Correlations
between GSRS-D scores and PTC GL-3 inclusion reduc-
tions suggest that PTC GL-3 inclusions are a potential
surrogate endpoint that may predict clinical outcomes
with migalastat treatment in Fabry disease. Given that
diarrhea occurs frequently and is highly troublesome in
Fabry disease, patients with an amenable GLA mutation
may derive meaningful symptom relief from treatment
with migalastat.
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